Clozapine 2025 – between efficacy and complications?
- Clozapine has been available on the market for a very long time, and the significance of this antipsychotic has been characterized by highs and lows. Recently, however, evidence is growing that clozapine is not only essential in severe treatment-resistant courses of schizophrenia, but that earlier use may be beneficial. Regardless, clozapine continues to be used approximately eight times less frequently than actually recommended by the guidelines. This care gap can be explained primarily by concerns about complications and the ongoing need for close monitoring of blood counts. It is now also slowly becoming apparent that agranulocytosis is not the biggest challenge in the use of clozapine.
